Brief: Novo Nordisk CEO Expects Data Next Year From Study Of Semaglutide In Alzheimer's Disease

Catalent

21/05/2024 15:37

May 21 (Reuters) - Novo Nordisk CEO Lars Fruergaard
Jorgensen: 
    * NOVO NORDISK CEO, ON LILLY'S DIABETES DRUG APPROVAL IN
CHINA,
SAYS "IT'S ONE MORE MARKET WHERE THERE WILL BE TWO CRITICAL
CONTENDERS COMPETING"
    * NOVO NORDISK CEO SAYS "SUPPLYING ALL WE CAN", THERE IS NO
DRUG
SHORTAGE OF OUR TYPE 2 DIABETES DRUG OZEMPIC IN THE US MARKET
    * NOVO NORDISK CEO ON COMPOUNDED VERSIONS OF CO'S DRUG
SEMAGLUTIDE
IN THE US SAYS "FOCUSED ON SECURING PATIENTS HAVE ACCESS TO HIGH
QUALITY PRODUCTS"
    * NOVO NORDISK CEO ON COMPOUNDED VERSIONS OF CO'S DRUG
SEMAGLUTIDE
IN THE US SAYS "WE CAN NOT VOUCH FOR THE QUALITY OF THOSE
MEDICINES"
    * NOVO NORDISK CEO SAYS CO IS CONDUCTING A LARGE PHASE 3
PROGRAM
EXPLORING THE BENEFIT OF USING SEMAGLUTIDE IN ALZHEIMER'S
DISEASE
    * NOVO NORDISK CEO SAYS EXPECTS CLINICAL DATA NEXT YEAR FROM
PHASE
3 PROGRAM OF SEMAGLUTIDE IN ALZHEIMER'S DISEASE
    * NOVO NORDISK CEO SAYS "OVER THE NEXT QUARTER SEEING A
STEADY
FLOW OF TRIAL DATA FOR SEMAGLUTIDE"
    * NOVO NORDISK CEO SAYS "WHEN WE NOW LAUNCH IN NEW
COUNTRIES, WE
WANT TO DO IT IN A WAY WHERE WE SET ASIDE A DEFINED CAPACITY"
FOR OBESITY DRUG
    * NOVO NORDISK CEO SAYS "PLEASED WITH" THE CATALENT
ACQUISITION
THAT WE'RE NOW WORKING ON AND WE EXPECT TO CLOSE IN THIS YEAR
    * NOVO NORDISK CEO SAYS CATALENT DEAL WILL BRING THREE LARGE
SITES
TO CO, AND THERE'S AMPLE EXPANSION OPPORTUNITY ON THOSE SITES
    * NOVO NORDISK CEO SAYS IN ADDITION TO CATALENT SITES, CO
WILL
CONTINUE WORKING WITH CONTRACT MANUFACTURERS
    * NOVO NORDISK CEO SAYS "THERE ARE A LOT OF CONTRACT
MANUFACTURERS
KNOCKING OUR DOOR ALMOST ON A WEEKLY BASIS"


Further company coverage:  NOVOb.CO 

 ((Reuters.Briefs@thomsonreuters.com;))